Spots Global Cancer Trial Database for Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers
Official Title: A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-small Cell Lung Cancers
Study ID: NCT05910827
Study Description
Brief Summary: This is a phase 1b multi-center, open-label study of HMBD-001 in combination with docetaxel with or without cetuximab in participants with locally advanced or metastatic squamous Non-Small Cell Lung Cancers
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
GenesisCare North Shore, Sydney, New South Wales, Australia
ICON Cancer Centre South Brisbane, Brisbane, Queensland, Australia
Southern Oncology Clinical Research Unit, Adelaide, South Australia, Australia
Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
Cabrini Health, Malvern, Victoria, Australia
Linear Clinical Research, Perth, Western Australia, Australia
National Cancer Centre Singapore, Singapore, , Singapore
Tan Tock Seng Hospital, Singapore, , Singapore
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
